Alterola Biotech Inc.

Market Cap $8.58M
Debt $313.67K
Cash $82.72K
EV $8.82M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$13.02M
EBIT	-$2.55M
ROA	-187%
Equity	-$2.05M
Growth Stability	1
PE	-0.66
PB	-4.18
Price/Cash	0.01
Debt/Equity	-0.15
Equity CAGR	4%
Earnings Growth YoY	-9K%
Earnings Growth QoQ	-2K%
Equity CAGR 5Y	-0%

Equity CAGR 3Y	-0%
Market Cap	$8.58M
Assets	$1.36M
Total Debt	$313.67K
Cash	$82.72K
Shares Outstanding	1.47B
EV	8.82M
Working Capital	-2.47M
Current Ratio	0.32
Shares Growth 3y	-4%
Equity Growth QoQ	40%
Equity Growth YoY	2%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Alterola Biotech Inc is a development stage company.

SEC Filings

Direct access to Alterola Biotech Inc. (ABTI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2023
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2022
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31

Sector Comparison

How does Alterola Biotech Inc. compare to its competitors?

Not enough data to generate a comparison chart between Alterola Biotech Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Alterola Biotech Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Alterola Biotech Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Alterola Biotech Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	03/2023	03/2024	TTM
Net Margins	-	-	-	-	-	-	-	-	-
ROA	-	-570%	-	-242%	-2K%	-2K%	-	-58K%	-187%
ROE	-	9%	23%	239%	128%	78%	-95%	934%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	03/2023	03/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-
Debt over Equity	-0.69	-0.73	-1.19	-0.36	-0	-	0.02	-0	-0.15
Growth Stability	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-0.15)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	03/2023	03/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-	-
Earnings YoY growth	-	-38%	200%	97%	94%	-3%	4K%	30%	-
Equity YoY growth	-	9%	12%	-81%	265%	59%	-3K%	-113%	-0%
FCF YoY growth	-	-	-	-	-	-	-	-	-